Gemin X Pharmaceuticals Completes $8M Series E Round of Financing
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, completed its $8m Series E round of financing. The round was led by Caxton Advantage Life Sciences Fund, L.P. and Sanderling Venture Partners, with participation from all of the company’s preferred stockholders. The company in April 2010 raised $16m in Series D […]